西藥品查詢
外觀圖示：
外觀描述：
粉紅色扁圓形錠劑，具剝半刻痕，錠劑上並印有SK及300字樣。
醫令代碼：
23256
商品名：
COLCHICINE TAB 0.5MG
中文名：
秋水仙鹼片
學名：
Colchicine
劑型：
TAB
孕婦用藥分級：
C 級
健保碼：
NC062711G0
藥品許可證：
內衛藥製字第006271號
仿單下載：
用藥指導單張：
ATC7藥理類別：
結構式 ：
Colchicine
N-((7S)-5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(a)heptalen-7-yl)-acetamide
UpToDate：
藥理作用 ：
本品能夠減少白血球產生尿酸，因此能夠降低尿酸的體內代謝，和損害白血球細胞膜的吞噬分解，而釋出組織中具有危險性的酶，這種藥物也會與微小管細胞蛋白質結合，所以會停止中期的有絲分裂和干擾活動細胞(如白血球)的運動。
適應症：
痛風。
用法用量：
通常成人一日Colchicine 3～4mg分6～8次口服，但依年齡、症狀得適量增減之。預防發病時，通常成人一日Colchicine 0.5~1mg，有發作之預感時，一次0.5mg口服。
副作用：
噁心、腹瀉、嘔吐。
藥物動力學：
Absorption
Rapidly absorbed. T max is 0.5 to 2 h.
Distribution
Large amounts present in bile and intestinal secretions. High concentrations also found in kidney, liver, and spleen. About 50% protein bound. Vd is 1 to 3 L/kg.
Metabolism
Undergoes enterohepatic recirculation. Deacetylated primarily by the liver.
Elimination
Plasma t ½ to 10 to 60 min. Excreted via biliary and renal routes; 10% to 20% excreted unchanged in urine.
交互作用：
Acidifying agents :
The action of colchicine is inhibited by acidifying agents. Avoid coadministration.
Alkalinizing agents:
The action of colchicine is potentiated by alkalinizing agents. Avoid coadministration.
CNS depressants :
Colchicine may increase sensitivity to the action of CNS depressants. Monitor the patient and adjust the CNS depressant dosage as needed.
Cyclosporine, digoxin, fibric acids (eg, fenofibrate, gemfibrozil), HMG-CoA reductase inhibitors (eg, atorvastatin, fluvastatin, pravastatin, simvastatin) ：
The risk of myopathy or rhabdomyolysis may be increased. If coadministration cannot be avoided, monitor the patient for signs of any unexplained muscle pain, tenderness, or weakness. If colchicine toxicity is suspected, discontinue colchicine.
Grapefruit juice ：
Colchicine plasma concentrations may be elevated by grapefruit juice ingestion, increasing the risk of toxicity (eg, myopathy). Advise patients taking colchicine not to consume grapefruit juice.
Moderate CYP3A4 inhibitors (eg, aprepitant, diltiazem, erythromycin, fluconazole, fosamprenavir, verapamil) ：
Colchicine plasma concentrations may be elevated, increasing the risk of toxicity (eg, myopathy). Coadminister with caution, starting at reduced colchicine doses, and increase monitoring of creatine phosphokinase and for adverse reactions. If colchicine toxicity is suspected, discontinue colchicine.
The action of colchicine is inhibited by acidifying agents. Avoid coadministration.
Alkalinizing agents:
The action of colchicine is potentiated by alkalinizing agents. Avoid coadministration.
CNS depressants :
Colchicine may increase sensitivity to the action of CNS depressants. Monitor the patient and adjust the CNS depressant dosage as needed.
Cyclosporine, digoxin, fibric acids (eg, fenofibrate, gemfibrozil), HMG-CoA reductase inhibitors (eg, atorvastatin, fluvastatin, pravastatin, simvastatin) ：
The risk of myopathy or rhabdomyolysis may be increased. If coadministration cannot be avoided, monitor the patient for signs of any unexplained muscle pain, tenderness, or weakness. If colchicine toxicity is suspected, discontinue colchicine.
Grapefruit juice ：
Colchicine plasma concentrations may be elevated by grapefruit juice ingestion, increasing the risk of toxicity (eg, myopathy). Advise patients taking colchicine not to consume grapefruit juice.
Moderate CYP3A4 inhibitors (eg, aprepitant, diltiazem, erythromycin, fluconazole, fosamprenavir, verapamil) ：
Colchicine plasma concentrations may be elevated, increasing the risk of toxicity (eg, myopathy). Coadminister with caution, starting at reduced colchicine doses, and increase monitoring of creatine phosphokinase and for adverse reactions. If colchicine toxicity is suspected, discontinue colchicine.
禁忌：
1. 嚴重的腎，胃腸，心臟，或肝的疾病。
2. 對Colchicine過敏患者禁止使用。
2. 對Colchicine過敏患者禁止使用。
注意事項：
由於長期投與，有時會引起血液障害、肝、腎帳害等，故用於預防疼痛發作時，請注意作檢尿，末梢血檢查(特別是白血球)以及肝功能定期檢查。
藥品保存方式：
避光容器中，15～30℃ 以下儲存。
